Eli Lilly and Company (LLY) Scheduled to Post Earnings on Tuesday

Eli Lilly and Company (NYSE:LLY) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, April 30th. Analysts expect Eli Lilly and Company to post earnings of $2.61 per share for the quarter. Eli Lilly and Company has set its FY 2024 guidance at 12.200-12.700 EPS and its FY24 guidance at $12.20-12.70 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS. On average, analysts expect Eli Lilly and Company to post $13 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $733.51 on Monday. The company has a market cap of $696.95 billion, a P/E ratio of 126.47, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business’s 50 day moving average price is $761.79 and its 200-day moving average price is $667.10. Eli Lilly and Company has a fifty-two week low of $380.77 and a fifty-two week high of $800.78.

Analysts Set New Price Targets

Several brokerages have commented on LLY. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 15th. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.